TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt(R) ...

Camp4 Therapeutics FY25 GAAP EPS missed expectations, but ended the year with a robust cash position. Check out why CAMP ...

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.

TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM ESTCompany ParticipantsBrett Monia - Founder, ...

On Thursday, 26 February 2026, Ionis Pharmaceuticals (NASDAQ:IONS) presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. CEO Brett Monia outlined the company’s ambitious plans ...

Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with ...

Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease- -Data support ...

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid ...

Salanersen, a treatment candidate for spinal muscular atrophy (SMA) now in clinical testing, is safe and was shown to stabilize or improve motor function over at least one year of follow-up in ...

Spinraza treatment led to sustained improvements in motor function in adults with SMA, according to a South Korean study.

An ongoing Phase III trial aims to further evaluate the drug's clinical efficacy in reducing seizures and affecting behavior and cognition.

Feb 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Tuesday the European Commission has approved a higher dose of its popular obesity drug Wegovy, providing patients and doctors with an ...